Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 4/20 | 0.86 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL25325582 | 1.00 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL1847525 | 1.00 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL7970993 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL6018271 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL27472975 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL6018269 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL2794532 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL5968698 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL1444822 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL27838573 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2TSHRALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0413289-B1 | Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | STERLING WINTHROP INC (US) | 1995-02-01 | — | — | EP | claimed |
| US-5159060-A | Cytotoxic boronic acid peptide analogs | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1992-10-27 | — | — | US | claimed |
| EP-0413289-A2 | Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | STERLING WINTHROP INC. (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0189448-B1 | AGENT FOR THE FLUORIDATION OF ORGANIC COMPOUNDS PARTICULARLY ACETYLENIC COMPOUNDS, PREPARATION PROCESS THEREOF AND UTILIZATION THEREOF IN NUCLEOPHILIC SUBSTITUTION OR ADDITION REACTIONS | UNIVERSITE D'ANGERS (FR) | 1989-01-25 | — | — | EP | claimed |
| JP-6135869-A | — | — | None | — | — | JP | disclosed |
| JP-5085971-A | — | — | None | — | — | JP | disclosed |
| CN-119790058-A | Fused cyclic KRAS inhibitors for the treatment of diseases | 荣山医药股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| EP-4472968-A1 | INHIBITORS OF RAF KINASES | PIERRE FABRE MEDICAMENT (FR) | 2024-12-11 | — | — | EP | disclosed |
| CN-110462402-B | Substance for preventing inhibition of antigen-antibody reaction by body fluid | 日本火腿株式会社 | 2024-06-25 | — | — | CN | disclosed |
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2024-06-06 | — | — | US | disclosed |
| US-11814384-B2 | Inhibtors of Raf kinases | KINNATE BIOPHARMA INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-09-28 | — | — | US | disclosed |
| EP-0503887-A2 | Promotion of wound-healing with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1992-09-16 | — | — | EP | disclosed |
| US-5110821-A | Picornavirus | STERLING DRUG INC. (US) | 1992-05-05 | — | — | US | disclosed |
| US-5106948-A | Anticarcinogenic agents | MAO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1992-04-21 | — | — | US | disclosed |
| EP-0467564-A2 | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |
| EP-0453127-A2 | Treatment of cataract with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1991-10-23 | — | — | EP | disclosed |
| EP-0413289-A2 | Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | STERLING WINTHROP INC. (US) | 1991-02-20 | — | — | EP | disclosed |
| US-4963655-A | ANTITUMOR AGENTS; VIRICIDES, AIDS, HERPES; ANTICANCER AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1990-10-16 | — | — | US | disclosed |
| US-4945164-A | 1,3,4-Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents and intermediates thereof | STERLING DRUG INC. (US) | 1990-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | SLC22A1 4606/4885SLC22A2 4655/4885TSHR 1226/4885 |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | SLC22A1 4606/4885SLC22A2 4655/4885TSHR 1226/4885 |
| US-11814384-B2 | Inhibtors of Raf kinases | RAF1, BRAF, ARAF | SLC22A1 4610/4885SLC22A2 4601/4885TSHR 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.